Intra-Cellular Therapies Announces Upcoming Presentations at the 4th Biennial Schizophrenia International Research Society Conference

NEW YORK, April 2, 2014 /GLOBE NEWSWIRE/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that one oral presentation and four posters on ITI-007, the Company’s lead drug candidate for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders, will be featured at the 4th Biennial Schizophrenia International Research Society (SIRS) Conference. The meeting will be held April 5-9, 2014, in Florence, Italy. The presentation and posters will feature data from ITI-007-005, the Company’s recently completed Phase 2 clinical trial in patients with an acutely exacerbated episode of schizophrenia, as well as data on the metabolism, unique target profile, and mechanism of action of ITI-007.

ITI-007-005 Trial Results


ITI-007-005 Poster Presentations

Poster #S78: “The novel pharmacology of ITI-007 is enhanced and extended by its metabolic back conversion from IC200131”. Robert Davis, et al. To be presented on Sunday, April 6th from 12:00 P.M. to 2:00 P.M. local time. Location: Cavaniglia Pavilion, Poster Session I.

Poster #S176: “Uniquely targeted molecular therapeutic for schizophrenia: characterization of ITI-007 in in vitro and in vivo animal models”. Lawrence Wennogle, et al. To be presented on Sunday, April 6th from 12:00 P.M. to 2.00 P.M. local time. Location: Cavaniglia Pavilion, Poster Session I.

Poster #M245: “Positive results with ITI-007 for the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled Phase 2 study”. Kimberly Vanover, et al. To be presented on Monday, April 7th from 12:00 P.M. to 2.00 P.M. local time. Location: Cavaniglia Pavilion, Poster Session II.

Poster #T221: “Mechanism of action of ITI-007: A novel therapy for the treatment of schizophrenia and related psychoses”. Gretchen Snyder, et al. To be presented on Tuesday, April 8th from 12:00 P.M. to 2.00 P.M. local time. Location: Cavaniglia Pavilion, Poster Session III.

About Intra-Cellular Therapies

Intra-Cellular Therapies (the "Company") is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the central nervous system ("CNS"). The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders. In December 2013, the Company announced positive topline results from the Company's randomized, placebo- and active-controlled Phase II clinical trial of ITI-007 in patients with acutely exacerbated schizophrenia. This study showed a statistically significant improvement in symptoms associated with schizophrenia at the 60 mg dose on the trial's pre-specified primary endpoint and a favorable safety profile. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of cognitive deficits in schizophrenia and other CNS disorders. The Company has partnered its lead PDE1 compound, ITI-214, and backups from this platform with the Takeda Pharmaceutical Company. ITI-214 has finished the first Phase 1 clinical trial and is now in subsequent Phase 1 trials. The Company is also developing inhibitors against additional targets for CNS indications such as Alzheimer's disease, Parkinson's disease and depression and non-CNS indications such as cardiovascular disease.

Contact:
Juan Sanchez, M.D.
Vice President
Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc.
Phone 212-923-3344

Burns McClellan, Inc.